Please Wait...

IGFBP-3 // Insulin-Like Growth Factor Binding Protein 3

Biomarker Therapeutic Areas: 
Biomarker Matrices: 

The majority of Insulin Like Growth Factors (IGFs) in serum is complexed with IGF Binding Proteins (IGFBP) and acid-labile subunit (ALS). Six IGFBPs have been cloned and identified. IGFBP3 has the highest binding capacity for IGF-1 and it prolonged its high life in serum. GFBPs in serum regulate the endocrine actions of IGFs by modulating bioavailable IGF (Mohan and Baylink, 2002). IGFBPs constitute a "buffer" capable of limiting the effect of a rise in IGF concentration (which could result in hypoglycemia) (Ranke, 2015). IGFBP3, through its binding with IGF-1, can also have a role in cancer cell growth and proliferation through a possible potentiation of IGF-1 signaling (Baxter, 2014).

Bioclinica Lab employs a high sensitive manual sandwich immunoassay for measurement of IGFBP3 in serum.

Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

With many clinical trials slowed or terminated, investments in new technologies are difficult. Yet, a #CTMS with a… https://t.co/VRIhWWf4tE
Bioclinica (5 days ago)
With Bioclinica #CTMS, sponsors & CROs have access to a full-featured, scalable system - a single, centralized sour… https://t.co/7ACrv8cvuF
Bioclinica (1 week ago)
Now available: a DIY #EDC solution. From study start-up to close-out, Bioclinica EDC Solo is an efficient, cost-eff… https://t.co/vFhC7ITfZV
Bioclinica (2 weeks ago)
Reduce the number of user requirement iterations and UAT findings during the #IRT build process. With the agile app… https://t.co/TJt2sZlrFP
Bioclinica (2 weeks ago)
Don't compromise with manual systems and spreadsheets. As an entry-level system with phased implementation, Bioclin… https://t.co/qIpi1MESXw
Bioclinica (3 weeks ago)
According to our recent poll, 45% of respondents had neither a #CTMS nor an #eTMF system, while only 24% had both.… https://t.co/l4dKC7pBQo
Bioclinica (3 weeks ago)